MGH study identifies key proteins linked to pregnancy hypertension disorders

Preeclampsia and other hypertensive disorders of pregnancy-;which are characterized by high blood pressure with or without organ dysfunction during the second half of pregnancy-;carry considerable short- and long-term risks for both the mother and child. Treatment options (other than expedited delivery) remain limited.

A team led by researchers at Massachusetts General Hospital (MGH) and the Broad Institute recently identified several proteins with strong evidence of causal or protective roles for hypertensive disorders of pregnancy, which could provide clues into how the conditions arise and how they might be prevented or treated.

In the study, which is published in JAMA Cardiology and involved genetic data from more than 600,000 individuals, the investigators tested whether a genetic predisposition to higher or lower levels of different proteins in the bloodstream influenced a woman's risk of developing hypertensive disorders of pregnancy.

The scientists identified six proteins involved in cardiovascular and inflammatory processes that likely contribute to or protect against these conditions. These included CD40, cystatin B, eosinophil cationic protein, galectin-3, heat shock protein 27, and N-terminal pro-B type natriuretic peptide.

These findings provide new insights into the biology of the hypertensive disorders of pregnancy, suggesting different pathways-;such as blood vessel regulation, inflammation, and immunity-;involved in the development of these diseases. Some of the proteins could serve as potential therapeutic targets and should be investigated further in animal models and ultimately, if promising, in human trials."

Michael C. Honigberg, MD, MPP, senior author, cardiologist and researcher at MGH and assistant professor of Medicine at Harvard Medical School

Additional authors include Art Schuermans, BSc; Buu Truong, MD; Maddalena Ardissino, MBBS; Rohan Bhukar, MS; Eric A. W. Slob, PhD; Tetsushi Nakao, MD, PhD; Jacqueline S. Dron, PhD; Aeron M. Small, MD, MTR; So Mi Jemma Cho, PhD; Zhi Yu, MB, PhD; Whitney Hornsby, PhD; Tajmara Antoine, BS; Kim Lannery, BS; Darina Postupaka, BA; Kathryn J. Gray, MD, PhD; Qi Yan, PhD; Adam S. Butterworth, PhD; Stephen Burgess, PhD; Malissa J. Wood, MD; Nandita S. Scott, MD; Colleen M. Harrington, MD; Amy A. Sarma, MD, MHS; Emily S. Lau, MD, MPH; Jason D. Roh, MD, MHS; James L. Januzzi Jr, MD; and Pradeep Natarajan, MD, MMSc.

This work was supported by the National Institutes of Health and American Heart Association.

Source:
Journal reference:

Schuermans, A., et al. (2024). Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia. JAMA Cardiology. doi.org/10.1001/jamacardio.2023.4994.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Antiseizure medications in pregnancy tied to child neurodevelopment risks